Northeast Financial Consultants’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Northeast Financial Consultants’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-577,262	Closed	-$358K	–	324
2018 Q4	$358K	Buy	+577,262	New	+$599K	0.05%	127
2018 Q3	–	Sell	-732,265	Closed	-$988K	–	185
2018 Q2	$988K	Hold	732,265	–	–	0.3%	47
2018 Q1	$1.06M	Hold	732,265	–	–	0.36%	43
2017 Q4	$1.65M	Hold	732,265	–	–	0.55%	34
2017 Q3	$2.49M	Hold	732,265	–	–	0.91%	23
2017 Q2	$2.6M	Hold	732,265	–	–	1.02%	21
2017 Q1	$2.49M	Hold	732,265	–	–	1.04%	19
2016 Q4	$3.37M	Hold	732,265	–	–	1.5%	12
2016 Q3	$3.1M	Buy	732,265 +697,239	+1,991%	+$2.26M	1.31%	18
2016 Q2	$84K	Buy	+35,026	New	+$127K	0.04%	146

Northeast Financial Consultants's AST Position: Q1 2019 in Review

Northeast Financial Consultants sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 577,262 shares — an estimated $358K sold.

Northeast Financial Consultants first reported a position in AST in Q2 2016 and held it in 10 quarters. The position peaked at $3.37M in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

Northeast Financial Consultants reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
Northeast Financial Consultants sold 577,262 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $358K.
Northeast Financial Consultants first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2016 and held it in 10 quarters.
Northeast Financial Consultants's Asterias Biotherapeutics Inc. Series A position peaked at $3.37M in Q4 2016.
0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Northeast Financial Consultants's 13F filing for Q1 2019, filed 14 May 2019.